If you want to meet a believer in the potential of cellular therapy to treat cancer, then look no further than Dr Cassian Yee.

Dr Yee is Director of Solid tumour Cell Therapy at the University of Texas MD Anderson Center in Houston and a Professor in the Departments of Melanoma Medical Oncology and Immunology.

He’s a pioneer in the development of endogeneous T cell therapy (ETC) that uses the peripheral blood as a source of antigen-specific T cells.

If the cells in the immune system are like the participants in “Game of Thrones” then Dr Yee’s eponymous car number plate and Twitter handle (@tcellsrus) strongly declares his allegiance.

He’s also co-founder of Immatics US, a company jointly founded back in 2015 by Immatics GmBH in Tubingen and MD Anderson, to commercialize next generation adoptive cellular therapy (ACT). The US venture secured $60M of first round funding, including $40M of funding from Immatics.

Dr Yee is not someone we’ve heard a lot from on the conference circuit in recent years, so it was a pleasure to catch up with him in person at the recent @C_IMT annual meeting in Mainz.

To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.

 

This content is restricted to subscribers

Posted by